Oxford Bundibugyo Ebola vaccine trial
Analysis based on 42 articles · First reported Jul 02, 2026 · Last updated Jul 24, 2026
The rapid development of a vaccine and diagnostic test for the Bundibugyo Ebola strain may reduce long-term economic disruption in affected regions and bolster confidence in pandemic preparedness. Pharmaceutical companies involved, such as AstraZeneca through its platform technology, could see reputational benefits.
The University of Oxford has launched the first human trial of a vaccine against the Bundibugyo strain of Ebola virus (ChAdOx1 BDBV), amid an ongoing outbreak in the Democratic Republic of the Congo and Uganda. The Phase I study will assess safety and immune response in 50 healthy adults in Oxford. The Serum Institute of India manufactured and stockpiled approximately 620,000 doses and supplied 4,000 investigational doses. The Coalition for Epidemic Preparedness Innovations funded the program with an $8.6 million grant. The World Health Organization added the first molecular diagnostic test for Bundibugyo virus to its Emergency Use Listing. As of July 11, the DRC reported 1,926 cases and 702 deaths; Uganda confirmed 20 cases and 2 deaths. Africa CDC expanded laboratory testing capacity. The vaccine reached human testing 57 days after WHO declared a Public Health Emergency of International Concern.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard